SenoRx Receives Food and Drug Administration Approval for Breast Cancer Treatment

Medical device maker SenoRx Inc. said Wednesday the Food and Drug Administration approved its breast cancer brachytherapy treatment.

Brachytherapy refers to the process of placing a radiation treatment inside or near the source of the cancer.

The Multi-Lumen Radiation Balloon Applicator is placed inside the area in need of radiotherapy. The approval is for therapy following lumpectomy for breast cancer.

Full launch of the product is expected in early 2008.

Shares of SenoRx jumped $1.10, or 13.8 percent, to $9.10 in morning trading. The stock has traded between $7.38 and $8.80 over the last 52 weeks.